Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Distributions of baseline variables by treatment arm, according to prognostic CLIP subgroups

From: Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma

Clip category 0–1 2–6 or unknown
  Tamoxifen (n = 85) Control (n = 94) Tamoxifen (n = 152) Control (n = 146)
Median (range) age (years) 66 (37–91) 66 (31–80) 65 (39–86) 67 (42–84)
Men 57 (67.1) 68 (72.3) 112 (73.7) 115 (78.8)
Evidence of disease at entry 77 (90.6) 86 (91.5) 141 (92.8) 137 (93.8)
Interval between diagnosis and entry     
   0–6 months 85 (100.0) 94 (100.0) 109 (71.7) 105 (71.9)
   7–12 months 0 (0.0) 0 (0.0) 21 (13.8) 19 (13.0)
   13–24 months 0 (0.0) 0 (0.0) 22 (14.5) 22 (15.1)
Child-Pugh category     
   A 62 (72.9) 67 (71.3) 53 (34.9) 51 (34.9)
   B 23 (27.1) 27 (28.7) 72 (47.4) 59 (40.4)
   C 0 (0.0) 0 (0.0) 26 (42.6) 35 (24.0)
   unknown 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.7)
Locoregional treatment     
   Surgery 10 (11.8) 10 (10.6) 8 (5.3) 5 (3.4)
   Percutaneous Ethanol Injection 34 (40.0) 46 (48.9) 30 (19.7) 32 (21.9)
   Transarterial chemoembolization 18 (21.2) 17 (18.1) 24 (15.8) 21 (14.4)
   none 23 (27.1) 21 (22.3) 90 (59.2) 88 (60.3)